Clinical Trial

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2024-11-18; most recent amendment 2026-06-05.
Status change: Active, Not Recruiting → Recruiting 2026-06-05
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Status change: Not Yet Recruiting → Recruiting 2025-01-30
Trial Details
NCT Number NCT06697184
Lead Sponsor BeOne Medicines
Conditions Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
Enrollment 258 participants
Start Date 2025-01-23
Primary Completion 2029-11-30 (estimated)
Study Completion 2032-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10